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Introduction
Abciximab and eptifibatide are antiplatelet drugs
which may reduce thrombotic complications in acute
coronary syndromes or after percutaneous coronary
interventions. Primarily, the function of human blood
platelets is the maintenance of haemostasis and arrest-
ing blood loss from the vessel. The fundamental part of
this process is platelet aggregation. However, this
aggregation is also the reason for thrombus (blood
clot) formation within the coronary artery, especially
in patients with acute coronary syndromes.
Blood platelets (thrombocytes) are an important
blood component. They play a significance role in the
process of thrombosis, hemostasis, clot retraction, host
defense, inflammation, tumor growth or metastasis,
maintenance and regulation of vascular tone [1].
Human blood platelets (PLT) are small non-nucleated
blood cells (approximately 2.0-4.0 μm in diameter).
Platelets are generated in the bone marrow by the
fragmentation of megakaryocyte [2] and circulate in
the organism for 7-10 days [3]. The platelets are com-
posed of platelet organelles such alpha and dense gran-
ule, mitochondria, lysosome, as well as an open
canalicular system and tubular system, cytoplasm,
granules of glycogen and plasma membrane surround-
ing the glycocalyx [4,5]. The glycocalyx contains gly-
coprotein, glycolipids, mucopolysacharides and
adsorbed plasma proteins [6]. Sialic acid is the glyco-
calyx component. The sialic acid causes a negative
charge of the platelet surface [7]. The glycoproteins on
the platelet surface are various receptors for adhesive
agents, aggregating agents, inhibitors and procoagu-
lant factors. For example, GP Ia/IIa and GP VI are col-
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lagen receptors, GP IIb/IIIa is a fibrinogen receptor, as
well as a von Willebrand factor receptor [5].
The platelet plasma membrane is a bilayer of phos-
pholipids with embedded proteins and cholesterol. The
phospholipid distribution in the platelet plasma mem-
brane is asymmetric [8]. Generally, in normal non-
treated platelets, 90% of sphingomyelin (SM), 45% of
phosphatidylcholine (PC) are in the outer monolayer,
and 90% of phosphatidylserine (PS), 80% of phos-
phatidylethanoloamine and most of the phosphatidyli-
nositol are in the inner monolayer [9].
The platelet aggregation process occurs in two
steps: platelet adhesion and platelet activation. After
adhesion, the platelet becomes activated involving a
series of morphologic and functional changes. The
activated platelet secrete the contents of the granule
and assumes an irregular shape with many extending
pseudopodia [10,11]. The platelet plasma membrane
with glycoproteins on its surface plays a very impor-
tant role in this process. The platelet phospholipids are
substrates for the formation of arachidonic acid. This
acid is the precursor of trombooxane (TXA2). Platelet
activation involves changes in membrane phospho-
lipid orientation: the phospahatidylserine (PS) and
phosphatidylethanoloamine (PE) surface expression is
observed. These changes are the reason for the proco-
agulant activity platelet surface [12].
Platelet aggregation is mediated by the glycoprotein
GPIIb/IIIa receptor. This receptor consists of two sub-
units,  αIIb and β3, and require Ca2+ for maintaining the
heterodimeric structure of the complex. The alpha sub-
unit is of 136-kDa and consists of a heavy chain and a
light chain. The heavy chain is entirely extracellular.
The light chain has a short cytoplasmic tail, a trans-
membrane region, and a small extracellular domain.
These two polypeptide chains are linked by a disulfide
bond. The beta subunit is of 92 kDa and consists of a
single polypeptide chain, with a short cytoplasmic tail, a
single transmembrane region, and a large extracellular
domain [13]. Platelet activation causes conformational
changes in the GP IIb/IIIa receptors, transforming the
receptors from a ligand-unreceptive to a ligand-recep-
tive state [14]. This glycoprotein is the most abundant
platelet receptor and a final step in thrombous forma-
tion, providing the unique possibility of designing
agents that specifically block the GPIIb/IIIa receptor
and prevent platelets from sticking together and causing
thrombus (blood clot) formation within the coronary
artery. This, especially in patients with acute coronary
syndromes [15]. Currently, there is a class of parenteral
drugs that specifically inhibit glycoprotein GPIIb/IIIa.
Three of them: the humanized Fab fragment of the mon-
oclonal antibody c7E3 i.e. abciximab (ReoPro), a cyclic
heptapeptide eptifibatide (Integrilin) and synthetic non-
peptide analog tirofiban (Aggrasrat) have been
approved for clinical use [16-18].
These drugs bind to the glycoprotein GPIIb/IIIa
and block the active centre receptor preventing the
binding of fibrinogen, the von Willebrand factor, and
other adhesive ligands to this receptor. 
Abciximab (M=48kDa) [19] is a Fab fragment of a
humanized monoclonal antibody c7E3. Abciximab
binds to the αIIbβ receptor through two binding sites:
RGD (Arg-Gly-Asp) and KQAGDV( Lys-Gln-Ala-
Gly-Asp-Val). This is a large molecule and the
inhibitory effect of abciximab may be due to the steric
hindrance of the ligand access [20]. Abciximab has a
short plasma half-life but a long duration of action as a
result of its high affinity for the receptor. Platelet func-
tion recovers within 24-48 hours after discontinuation
of this agent [21]. 
Eptifibatide is a cyclic heptapeptide containing six
amino acids with a characteristic amino acid sequence
Lys-Gly-Asp (KGD) and one mercaptopropionyl (des-
amino cysteinyl) residue. It is a relatively small mole-
cule (M<1kDa) [19] that fits into the RGD motif bind-
ing pocket of glycoprotein GPIIb/IIIa and blocks the
fibrinogen junction to the receptor [22]. Eptifibatide is
characterized by a short half-life and normal platelet
function is restored within 2 to 4 hours after treatment
termination [21].
Platelet functions were investigated in many
respects. Blending time, percentage of aggregation
platelet, ultrastructural evaluation of platelets [1,23]
were investigated, as well as the composition and
organization of the platelet membrane lipid [9,24,25],
and the interaction between platelet membrane compo-
nents [26-28] and drugs [29]. The interaction between
proteins and lipids was observed by negative staining
electron microscopy [26], capillary electrophoresis
with laser-induced fluorescence detection [30] and
Surface Plasmon Resonance [31,32]. Chromatography
methods such as two dimensional thin-layer chro-
matography [33], high performance thin layer chro-
matography [34], or high performance liquid chro-
matography [35] were used for analysis of the phos-
pholipid composition of platelet membranes. 
The aim of this work was the investigation of the
interaction between the phospholipid-GPIIb/IIIa gly-
coprotein complex and antiaggregate drugs such as
abciximab or eptifibatide, as well as the influence of
these drugs on the phospholipid ratio in the platelet
membrane.
Materials and methods
Measuring apparatus. HPLC analysis was done using a Merck
Hitachi liquid chromatograph with a diode array detector (model
L-4500, Tokyo Japan). A Superspher Si 60 column (250×4 mm)
was applied.
SPRI measurements were performed as described in a previous
paper [36-38]. Briefly, the measurements were performed at a
fixed angle of incident light and reflectivity was simultaneously
measured across an entire chip surface. The contrast values
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obtained for all pixels across a particular sample spot were inte-
grated. Thus the SPRI signal was integrated over the spot area.
NIH Image J version 1.32 software was used to evaluate the SPRI
images in 2D form.
Chemicals. Phosphoric acid, sodium chloride, sodium hydrogen
carbonate, sodium dihydrogen phosphate, potassium chloride,
magnesium chloride, chloroform (all analytical grade, POCH, Gli-
wice, Poland), Tyrode buffer (12 mM NaHCO3, 4 mM NaH2PO4,
137 mM NaCl, 2,6 mM KCl, 1 mM MgCl2, pH 7.3), butylated
hydroxytoluene (BHT), 1-octadecanethiol ODM (analytical grade
SIGMA-ALDRICH), acetonitrile, methanol, n-hexane, iso-
propanol (all gradient grade for chromatography, MERCK),
absolute ethanol (Eurochem BGD, Tarnow, Poland), phospholipids
standards- phosphatidylinositol (porcine liver), phosphatidylserine
(bovine brain), phosphatidylethanolamine (porcine liver), phos-
phatidylcholine (porcine liver) and sphingomyelin (porcine liver)
((Larodan AB, Sweden), abciximab (REOPRO, Centocor B.V.
Holand), eptifibatide (INTEGRILIN, Glaxo Group Ltd, Great Bri-
tain), glycoprotein GPIIb/IIIa (CALBIOCHEM, Merck group,
Merck Sp. z.o.o., Warsaw, Poland), photopolymer ELPEMER SD
2054, hydrophobic protective paint SD 2368 UV SG-DG
(PETERS, Kempen, Germany) were used as received. Water was
deionized with a MiliQ (Milipore) apparatus. 
Chip preparation. Gold chips were manufactured as described in
the previous paper [36].
Photopolymer deposition. Gold chips were rinsed with ethanol
and dried under a stream of nitrogen. A photopolymer layer was
then deposited over the gold layer by a screen printing technique.
Photopolymer was dried at 70°C for 30 minutes and irradiated with
UV light (800 W) from a distance of 30 cm for 2 minutes. The pho-
topolymer was developed with 1% aqueous sodium carbonate,
washed with redistilled water and dried. The photopolymer layer
was covered with a hydrophobic protective paint, as well as by
application of the screen printing technique. The paint was irradi-
ated for 5 minutes with a UV lamp (800 W). Free gold surfaces of
the obtained sensor were separated with a photopolymer and
hydrophobic paint. Therefore, four different solutions can be
simultaneously measured without mixing the tested solutions.
Phospholipids immobilization. Chips with a photopolymer grid
were rinsed with ethanol and water and dried under a stream of nitro-
gen. They were then immersed in 2,7 mM ODM ethanolic solutions
for at least 24 h. The chips were further rinsed with ethanol and
water and dried under a stream of nitrogen. The phospholipids solu-
tions (10 mM) were prepared in a chloroform-methanol mixture
(2:1, v/v). These solutions were evaporated to dryness and dissolved
in 200 μl of water under energy shaking. The phospholipid suspen-
sion was placed on the chips for at least 24 h.
Procedure of interaction study. The chips with the phospho-
lipid layer were washed 3 times with water and dried under a
stream of nitrogen. The aqueous glycoprotein IIb/IIIa solution
(C=50 μg/ml) was placed on the chips and incubated at 37°C for
1h. The surface of the chips was washed 3 times with water. The
chips were placed on the prism in the apparatus and then the SPR
signal was measured. It was the signal before the interaction of the
phospholipid-glycoprotein complex with a drug. A drop of drug
solution (abciximab C=3.57 μg/ml; eptifibatide C=2.56 μg/ml)
was located on the chips for 30 min of interaction time. The drug
solution was removed, the chip surface was washed with the buffer
and the SPR measurement was performed again.
Isolation and analysis of platelet phospholipids by HPLC
methods. Human platelets were prepared from whole blood, taken
from healthy volunteers supplied by the Blood Donor Centre in
Bialystok. The blood was incubated with drugs at a therapeutic
concentration: abciximab (3.57 μg/ml of blood) for 0.5 hour, 
4 hours, 24 hours or eptifibatide (2.57 μg/ml of blood) for 0.5 hour,
1 hour and 4 hours. The platelet rich plasma was separated by cen-
trifuging blood at 130 g for 8 min at room temperature. This
platelet rich plasma was then centrifuged at 2200 g for 10 min. to
obtain a platelet bottom. The supernatant was removed. The
platelet bottoms were washed three times with isotonic saline. 
The lipid fraction was extracted by using 15 ml n-hexane-iso-
propanol mixture (3:2, v/v) [39]. The whole, after stirring and shak-
ing, was centrifuged at 4000 g for 20 min. The lipids extract was
evaporated to dryness under nitrogen (N2). To prevent the oxidation
of phospholipids during extraction, 0.03% of BHT was added, along
with flushing with nitrogen at each step of the procedure.
Individual phospholipids were separated by liquid chromatog-
raphy in a normal phase system (NP-HPLC) with column Si60, UV
detection and isocratic elution. The mobile phase was an acetoni-
trile-methanol-85% phosphoric acid mixture of 130:5:1.5 volume
ratio. The flow-rate of the mobile phase was 1 ml/min. Chro-
matogram was recorded at 214 nm wavelength [40]. The peaks of
phosphatidylinositol (PI), phosphatidylserine (PS), phos-
phatidylethanolamine (PE) and phosphatidylcholine (PC) are well
separated.
Statistical analysis. The results are expressed as mean values ±SD
(n=9, abciximab; n=13, eptifibatide). Statistically significant dif-
ferences were determined by the Student's t-test, as well as
ANOVA. p≤0.05 was considered statistically significant.
Results and discussion
SPR investigation of phospholipids-GP
IIb/IIIa-drugs interactions
The purpose of these experiments was to exhibit inter-
actions between various immobilized phospholipids
(PI, PS, PE, PC, SM) and glycoprotein GPIIb/IIIa, as
well as the interaction between the immobilized phos-
pholipid-glycoprotein GPIIb/IIIa complex and
antiplatelet drugs abciximab or eptifibatide. Phos-
phatidylinositol (PI), phosphatidylserine (PS), phos-
phatidylethanolamine (PE), phosphatidylcholine (PC)
and sphingomyelin (SM) were first immobilized onto
the chip surface. The increase in the signal was
observed after interaction of each phospholipid with
glycoprotein, showing their mutual interactions.
Human albumin was used in the investigation as a
comparative protein. When human albumin was used,
no binding of any type of phospholipids was observed.
The sequence of GPIIb/IIIa affinity to the investigated
immobilized phospholipids is: PS>PC>PE>SM>>PI.
The greatest increase in the SPR signal was
observed with phosphatidylserine, which indicates that
glycoprotein exhibits the biggest affinity with these
phospholipids. Phosphatidylserine is a very important
phospholipid in the process of platelet activation and
aggregation. The increase in the negative charge of the
membrane surface is necessary for the achievement
of procoagulant properties. This condition is met
when negatively-charged PS is transported from the
inner monolayer of cell membrane to its outer mono-
layer [12,41,42]. Other phospholipids are capable of
modulating the PS coagulant effect. According to
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Heemskerk [43], PE strengthens the procoagulant
properties of the membrane whereas SM weak them.
According to Parise and Philips [26] GPIIb/IIIa is the
most easily incorporated into the vesicles with the
biggest content of PS in the presence of PC. These
authors supposed that one of the reasons for strong PS
interactions with GPIIb/IIIa may be interactions
between an acidic group of PS and the positive charge
of GPIIb/IIIa. Negatively charged membrane phospho-
lipids enable dense parallel protein sticking and
anchoring in the membrane. PS may cause the defect
in the bilayer membrane structure, which causes better
GPIIb/IIIa anchoring [26]. Sequence of GPIIb/IIIa
affinity to other phospholipids is as follows:
PC>PE>SM. The percentage of PC in membrane
phospholipids is the greatest (about 40%) [44].
The data found in the literature [26,45] suggest that
interactions PE with certain receptors is similar to PS.
PE is moved to the outer part of membrane during the
activation process.
The results of the interaction between the immobi-
lized phospholipid-complex glycoprotein GPIIb/IIIa
and abciximab or eptifibatide are shown in Figure 2.
All complexes exhibit strong interaction with both
drugs. This interaction follows the sequence: PS<
PI<PC<PE<SM. Strong interactions between both
investigated drugs and complexes of phospholipids
with glycoprotein GPIIb/IIIa confirm that the role of
the drugs is the inactivation of glycoprotein GPIIb/IIIa
active areas.
In most cases, the signal increase after interaction
of the phospholipid-glycoprotein GPIIb/IIIa complex
with the drugs was smaller for abciximab than for epti-
fibatide. 
Eptifibatide is a more specific drug than abciximab.
It bonds only with a GPIIb/IIIa receptor [22]. It incor-
porates into the notch between the arms of GPIIb/IIIa.
Several hundred drug molecules join to the single
GPIIb/IIIa molecule [46]. Eptifibatide molecules can be
combined forming aggregates [11] and can be the rea-
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Fig. 1. Increase in the SPR signal after interaction of immobilized
phospholipids with glycoprotein GPIIb/IIIa. PI – phosphatidyli-
nositol, PS – phosphatidylserine, PC – phosphatidylcholine, PE –
phosphatidylethanolamine, and SM – sphingomyelin.
Fig. 3. Comparison of the phospholipid content in platelet mem-
branes as a percentage of the total phospholipids in platelets treat-
ed and untreated with abciximab (n=9).  Statistically significant
differences for p≤0.05 with respect to control.
Fig. 4. Comparison of the phospholipid content in platelet mem-
branes as a percentage of the total phospholipids in platelets treat-
ed and untreated with eptifibatide (n=13).  Statistically significant
differences for p≤0.05 with respect to control.
Fig. 2. Increase in the SPR signal after interaction of immobilized
phospholipid- complex glycoprotein GPIIb/IIIa with abciximab or
eptifibatide. PI – phosphatidylinositol, PS -phosphatidylserine, PC
– phosphatidylcholine, PE – phosphatidylethanolamine, and SM –
sphingomyelin. 
son for a SPR signal increase dependent on mass.
Abciximab incorporates into two active areas, GP RGD
and KQAGDU [20]. It is a large molecule and acts as a
spherical bloc by covering glycoprotein. 1.5 abciximab
molecules joins one GPIIb/IIIa molecule [46].
In vitro investigation of interaction of 
abciximab and eptifibatide with human platelets
in terms of the phospholipid ratio
Human blood platelets were in vitro treated with anti-
coagulant drugs abciximab and eptifibatide. After
treatment, the phospholipid ratio in cellular mem-
branes was investigated.
Four classes of phospholipids: phosphatidylinositol
(PI), phosphatidylserine (PS), phosphatidylethano-
lamine (PE) and phosphatidylcholine (PC) were isolat-
ed from blood platelets and determined using the
HPLC method. Under these conditions, sphingomyelin
was not determined. The ratio of particular phospho-
lipids in the mixture was calculated as a percentage of
the phospholipid  peak area in the total area of all
peaks.
Figures 3 and 4 show changes in the composition of
phospholipids isolated from blood platelets treated
with abciximab (Fig. 3) or eptifibatide (Fig. 4).
The investigations demonstrate that both drugs
affect the percentage of phosphatidylcholine and phos-
phatidylserine. There occurs a statistically significant
drop of phosphatidylserine level and a concurrent
increase in phosphatidylcholine content within a half
an hour of the moment of adding the drugs to blood, in
comparison to the control sample, which was donor's
blood without the drug. In the case of blood incubation
with abciximab, PS content decreases by 55% of the
initial value of phospholipids isolated from the sample
whereas in the case of eptifibatide decreases by 39.5%.
Simultaneously, the increase in the level of PC by
approximately 17% is observed both for abciximab
and for eptifibatide. Percentage composition of phos-
phatidylethanolamine and phosphatidylinositol oscil-
lates within the margin of error. Figs. 3 and 4 indicate
that these changes are reversible and the percentage
composition of phospholipids gradually reverses. The
reversibility of observed changes in the phospholipid
ratio is caused by a gradual reduction of the drug activ-
ity. Abciximab quickly fixes with the GPIIb/IIIa recep-
tor, concentration of free antibody in blood plasma
drops quickly (30 minutes half life). Reversibility of
the action is slow and the appropriate function of
platelets returns after 24 hours [21]. Eptifibatide fixes
to the receptor quickly and disassociates it as quickly,
which means that its anti-aggregation effect is divert-
ed after approximately 4 hours [21].
Decreasing PS level and increasing PC level simul-
taneously indicates that their mutual transformations
in a cell are significant. The acceleration of the PS
decarboxylation process and its further changes lead-
ing to PC formation are likely to occur [47].
Full content of the phospholipid isolate does not
change in a statistically significant way. 
Conclusions
Human platelets treated 'in vitro' with anticoagulant
drugs abciximab or eptifibatide exhibit changes in the
phospholipid ratio in the platelet membrane. The ratio
of PS decreases and the ratio of PC rises. 
The SPRI technique distinctly shows interactions
between phospholipids and glycoprotein GPIIb/IIIa, as
well as between the phospholipid-glycoprotein
GPIIb/IIIa complex and abciximab or eptifibatide. The
interaction between phospholipids and glycoprotein
GPIIb/IIIa follows the sequence: PI<<SM<PE
<PC<PS. The interaction between the phospholipid-
glycoprotein GPIIb/IIIa complex and abciximab fol-
lows the sequence: PS<PI<PC<PE<SM, while with
the eptifibatide follows the sequence: PS,PI<PC
<PE<SM. Generally, the interactions between the
phospholipid-glycoprotein GPIIb/IIIa complex and
eptifibatide are stronger than those with abciximab.
SPRI was proved to be an excellent tool for the obser-
vation of such kinds of interactions.
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